{"name":"Neurodawn Pharmaceutical Co., Ltd.","slug":"neurodawn-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNVV8yVDZWcm16UGV3bkJ5SnB1dzlHQ3VVZnNkY0dOMS1iQmNodlpiSHdldEFPTVo1d2wtWklTVzRXVHNvaWRKSkV1YURTNzVQZDVJemV4OFdKV2JKQ2llZ2FYaUx6MUlEQVRPLUxsV0pQQTBkOWFib1B2MjQyczhDMXVOM29BNjRreEFUbFpYWEM0VGZvMWZ1eks4eG5UVUFjcUZrelV0WHlVT1RQMVQteUdUcFo0LVpjRUtTQ2JkYzZEUlpKZURhUk9sTXA3N05WcEJuaUJSUndVM0NQUWQtYTF1alNKaWVRaklnZ3N1RFNjRkIzNlE?oc=5","date":"2024-12-02","type":"regulatory","source":"Citeline News & Insights","summary":"Simcere’s Sublingual Edaravone Nears International Phase III Trial After China Approval - Citeline News & Insights","headline":"Simcere’s Sublingual Edaravone Nears International Phase III Trial After China Approval - Citeline News & Insights","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQWGU1YmRLanE3WFBlek1TMU5MdWphTFdvSXJhTmlfNkdpLTRPaFdxd0lrVUVJTWxEeGNvOHdzdUdHSWtHQng3ejRYZDc1Z2xYcVBhRUg1OEhXeklET0xXanZ1VV9zQWdXZS1PQ19fZnZuSWlDVFhvb0dHTlRfWGtyV2FzS0xuWlhmQTVfTndleEstYVE0LXNwZXo4RzRmSUp4djdFaTZiNkY0ZXVJakVyOVJWTHplU1pGS1drOHBQeG9GQWU1RmJBeTRwM0FpaUo4NFlfU2ZZOEs4Q00?oc=5","date":"2024-02-20","type":"trial","source":"PR Newswire","summary":"Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA - PR Newswire","headline":"Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}